Recursion director sells shares in pre-planned trade
RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade. On this Form 4, Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals, so the sale reflects only a portion of the director’s overall stake.
Insider Trade Summary 10b5-1
Net Seller: 4,386 shares
Net Sell
1 txn
Insider
Bumpus Namandje
Role
Director
Sold
4,386 shs ($16K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock | 4,386 | $3.54 | $16K |
Holdings After Transaction:
Class A Common Stock — 43,171 shares (Direct)
Footnotes (1)
- F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
Key Figures
Shares sold: 4,386 shares
Sale price: $3.54 per share
Shares held after transaction: 43,171 shares
+1 more
4 metrics
Shares sold
4,386 shares
Open-market sale of Class A Common Stock
Sale price
$3.54 per share
Average price for the 4,386-share sale
Shares held after transaction
43,171 shares
Director’s direct holdings following the sale
Rule 10b5-1 plan adoption date
March 3, 2026
Plan governing the reported sale
Key Terms
Form 4, Rule 10b5-1 trading plan, open-market sale, Class A common stock
4 terms
Form 4 regulatory
"reported selling 4,386 shares of Recursion Pharmaceuticals Class A common stock at an average price of $3.54 per share, documented as a routine insider trading disclosure on Form 4"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Rule 10b5-1 trading plan regulatory
"The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"Bumpus reported an open-market sale of 4,386 shares of Class A common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Class A common stock financial
"Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Recursion Pharmaceuticals (RXRX) director Namandje Bumpus report on this Form 4?
Director Namandje Bumpus reported selling 4,386 shares of Recursion Pharmaceuticals Class A common stock. The transaction was an open-market sale at an average price of $3.54 per share, documented as a routine insider trading disclosure on Form 4.
Was the RXRX insider sale by Namandje Bumpus under a Rule 10b5-1 plan?
Yes. The Form 4 footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026. Such plans pre-schedule trades, reducing the significance of the exact timing of this 4,386-share open-market sale.
Is the Namandje Bumpus Form 4 sale a buy or a sell signal for RXRX investors?
The filing shows a sale, not a purchase, of 4,386 shares at $3.54. However, the transaction occurred under a pre-arranged Rule 10b5-1 plan and Bumpus still holds 43,171 shares, suggesting a routine diversification rather than a clear directional signal.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates